Alnylam Pharmaceuticals Inc (ALNY) - Medical Equipment - Deals and Alliances Profile

Alnylam Pharmaceuticals Inc (ALNY) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME66532D
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Alnylam Pharmaceuticals Inc, Medical Equipment, Deal Details 11

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11

Equity Offering 12

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 19

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 20

Alnylam Pharmaceuticals Inc-Key Competitors 22

Alnylam Pharmaceuticals Inc-Key Employees 23

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 25

Recent Developments 26

Financial Announcements 26

Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 26

May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 30

Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 33

Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 36

May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 38

Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 40

Corporate Communications 43

Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 43

Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 44

May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 45

Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 46

May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 47

Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 49

Legal and Regulatory 50

Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 50

Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 51

Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 52

Product News 53

Oct 11, 2018: US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam 53

Jun 12, 2017: Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

List of Tables

Alnylam Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Alnylam Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 9

Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11

Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12

Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14

Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16

Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18

Alnylam Pharma Completes Public Offering Of Shares For USD 185 Million 19

Alnylam Pharma Completes Public Offering Of Shares For USD 93 Million 20

Alnylam Pharmaceuticals Inc, Key Competitors 22

Alnylam Pharmaceuticals Inc, Key Employees 23

Alnylam Pharmaceuticals Inc, Subsidiaries 24

Alnylam Pharmaceuticals Inc, Joint Venture 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alnylam Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com